Taysha Gene Therapies, Inc.

Good morning. Welcome to Tayshia Gene Therapy's first quarter 2022 financial results and corporate update conference call. At this time, all participants are in a listen-only mode. Following management's prepared remarks, we will hold a brief question and answer session. As a reminder, this call is being recorded today, May 16, 2022. I'll now turn the call over to Dr. Kimberly Lee, Chief Corporate Affairs Officer. Please go ahead.

Good morning and welcome to Tayshia's first quarter 2022 financial results and corporate update conference call. Joining me on today's call are Ari Session II, Tayshia's president, founder, and CEO, Dr. Suresh Prasad, chief medical officer and head of R&D, and Cameron Alam, chief financial officer. After a formal remark, we will conduct a question and answer session and instructions will follow at that time. Earlier today, Tayshia Institute of Press release announcing financial results for the first quarter ended March 31st, 2022. A copy of this press release is available on the company's website and through our SEC filings. Please note that on today's call, we will be making forward-looking statements, including statements relating to the safety and efficacy and the therapeutic and commercial potential of our investigational product candidates. These statements may include the expected timing and results of clinical trials for our product candidates, our expectations regarding the data necessary to support regulatory approval of TASHA 120, and the regulatory status and market opportunity for those programs, as well as Tayshia's manufacturing plans. This call may also contain forward-looking statements relating to Tayshia's growth and future operating results, discovery and development of product candidates, strategic alliances and intellectual property, as well as matters that are not of historical facts or information. Various risks may cause Tayshia's action results to differ materially from those stated or implied in such forward-looking statements. These risks include uncertainties related to the timing and results of clinical trials and pre-clinical studies of our product candidates, our dependence upon strategic alliances and other third-party relationships, our ability to obtain patent protection for our discoveries, limitations imposed by patents owned or controlled by third parties, and the requirements of substantial funding to conduct our research and development activities. For a list and description of the risks and uncertainties that we face, please see the reports we have filed with the Securities and Exchange Commission. This conference call contains time-sensitive information that is accurate only as of today of this live broadcast, May 16, 2022. Tisha undertakes no obligation to revise or update any forward-looking statements to reflect events or circumstances after the date of this conference call, except as may be required by applicable securities law. I would now like to turn the call over to our President, Founder, and CEO, Ari Session II. Ari?

Thank you, Kim. Good morning and welcome, everyone, to our first quarter 2022 Financial Results and Corporate Update conference call. Since our last update, we have continued to advance our core development programs with particular focus on gynexonal neuropathy, or GAN, and Rett syndrome. In March, we were pleased to initiate clinical development of TASHA-102 under a CTA approved by Health Canada for the first and only gene therapy and clinical development for Rett. which affects over 350,000 patients worldwide. We look forward to reporting preliminary Phase I-II clinical safety and efficacy data by year-end. We were also pleased to recently receive Orphan Drug Designation for TASHA-120 for gynexonal neuropathy from the European Commission, further highlighting the unmet need for treatment options in GAN and the potential of TASHA-120 to provide a disease-modifying treatment for these patients. We look forward to providing a regulatory update by mid-2022. As we look ahead, we remain focused on executing on our strategic pipeline prioritization initiatives and expect our current capital resources, along with full access to our existing term loan facility, to fund operating expenses and capital requirements into the fourth quarter of 2023. I will now turn the call over to Suyesh to provide a more detailed update on our clinical programs. Suyesh, please go ahead.